Natixis Advisors LLC Reduces Stock Position in Genmab A/S (NASDAQ:GMAB)

Natixis Advisors LLC lessened its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 32.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 159,126 shares of the company's stock after selling 76,848 shares during the period. Natixis Advisors LLC's holdings in Genmab A/S were worth $3,999,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Capital International Investors raised its holdings in shares of Genmab A/S by 7.8% during the first quarter. Capital International Investors now owns 4,373,277 shares of the company's stock valued at $130,805,000 after purchasing an additional 315,355 shares during the last quarter. Harding Loevner LP increased its position in shares of Genmab A/S by 2.7% during the 4th quarter. Harding Loevner LP now owns 3,289,895 shares of the company's stock valued at $97,569,000 after purchasing an additional 85,665 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of Genmab A/S by 16.0% in the fourth quarter. First Trust Advisors LP now owns 1,270,095 shares of the company's stock worth $40,440,000 after buying an additional 175,292 shares during the last quarter. Ingalls & Snyder LLC boosted its stake in shares of Genmab A/S by 29.3% during the 2nd quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company's stock worth $5,772,000 after acquiring an additional 52,117 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in shares of Genmab A/S by 5.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 165,187 shares of the company's stock worth $5,260,000 after purchasing an additional 8,463 shares in the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Price Performance

Shares of Genmab A/S stock traded down $0.17 during trading hours on Friday, reaching $27.52. The company's stock had a trading volume of 370,163 shares, compared to its average volume of 577,660. Genmab A/S has a one year low of $24.53 and a one year high of $38.80. The firm has a 50 day moving average price of $27.05 and a 200-day moving average price of $28.13. The stock has a market cap of $18.20 billion, a P/E ratio of 22.93, a P/E/G ratio of 0.88 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). The company had revenue of $779.50 million for the quarter, compared to the consensus estimate of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. As a group, sell-side analysts forecast that Genmab A/S will post 1.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GMAB has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Truist Financial upped their price objective on Genmab A/S from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Tuesday, June 4th. Morgan Stanley reissued an "equal weight" rating and set a $31.00 target price on shares of Genmab A/S in a research note on Wednesday. Royal Bank of Canada upgraded Genmab A/S from a "sector perform" rating to an "outperform" rating in a research note on Monday, July 15th. Finally, HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Tuesday, August 27th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $45.80.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.